Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure

• DOI: 10.1007/s11010-021-04159-5
• Publication Date: 2021-05-11T12:03:44Z
• Authors: Juntuo Zhou; Xi Chen; Wei Chen; Lijun Zhong; Ming Cui
• Keywords: Heart Failure; Male; Middle Aged; Lipids; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; ROC Curve; Case-Control Studies; Lipidomics; Metabolome; Humans; Biomarkers; Aged

Heart failure is a syndrome with symptoms or signs caused by cardiac dysfunction. In clinic, four stages (A, B, C, and D) were used to describe heart failure progression. This study was aimed to explore plasma metabolomic and lipidomic profiles in different HF stages to identify potential biomarkers. Metabolomics and lipidomics were performed using plasma of heart failure patients at stages A (n = 49), B (n = 61), and C+D (n = 26). Analysis of Variance (ANOVA) was used for screening dysregulated molecules. Bioinformatics was used to retrieve perturbed metabolic pathways. Univariate and multivariate receiver operating characteristic curve (ROC) analyses were used for potential biomarker screening. Stage A showed significant difference to other stages, and 142 dysregulated lipids and 134 dysregulated metabolites were found belonging to several metabolic pathways. Several marker panels were proposed for the diagnosis of heart failure stage A versus stage B-D. Several molecules, including lysophosphatidylcholine 18:2, cholesteryl ester 18:1, alanine, choline, and Fructose, were found correlated with B-type natriuretic peptide or left ventricular ejection fractions. In summary, using untargeted metabolomic and lipidomic profiling, several dysregulated small molecules were successfully identified between HF stages A and B-D. These molecules would provide valuable information for further pathological researches and biomarker development.